Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience
Objectives - A phase II trial investigating the therapeutic effect of neoadjuvant programmed cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to surgery for the treatment of non-small cell lung cancer (NSCLC) has been conducted (NCT03197467). We report the first cl...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
21 January 2021
|
| In: |
Lung cancer
Year: 2021, Volume: 153, Pages: 150-157 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2021.01.018 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.lungcan.2021.01.018 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0169500221000362 |
| Author Notes: | Florian Eichhorn, Laura V. Klotz, Mark Kriegsmann, Helge Bischoff, Marc A. Schneider, Thomas Muley, Katharina Kriegsmann, Uwe Haberkorn, Claus Peter Heussel, Rajkumar Savai, Inka Zoernig, Dirk Jaeger, Michael Thomas, Hans Hoffmann, Hauke Winter, Martin E. Eichhorn |
Search Result 1
Search Result 2
Search Result 3
Search Result 4